Companies: 10,795·Total market cap: $144.5T
Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

NVCTNASDAQHealthcare● Active
$9.42
$-0.12(-1.26%)
Market Cap$249870521
P/E Ratio
52W High$13.34
52W Low$5.55
SEC Filings

Nuvectis Pharma, Inc. (NVCT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001875558 · NVCT · NASDAQ · as of Jun 9, 2026

Filing snapshot

254
Total Filings
10-Q
Latest Form
2026-05-05
Most Recent
2022
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001875558 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-11
Fiscal Year End
Feb 11, 2026
Accession No.
0001104659-26-013044
Primary Document
tmb-20251231x10k.htm
Source: data.sec.gov · CIK 0001875558 · Accession 0001104659-26-013044

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-05
8-KCurrent Report
FORM 8-K
2026-05-05Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-05
View
8-KCurrent Report
FORM 8-K
2026-05-05
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-27
View
DEF 14AProxy Statement
DEF 14A
2026-04-27
View
EFFECTEFFECT
EFFECT
2026-02-20
View
CORRESPCORRESP
CORRESP
2026-02-18
View
UPLOADUPLOAD
UPLOAD
2026-02-18
View
S-3Shelf Registration
FORM S-3
2026-02-13
View
8-KCurrent Report
FORM 8-K
2026-02-11
View
10-KAnnual Report
10-K
2026-02-11
View
8-KCurrent Report
FORM 8-K
2025-11-04
View
10-QQuarterly Report
10-Q
2025-11-04
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2025-10-31
View
8-KCurrent Report
FORM 8-K
2025-09-25
View
10-QQuarterly Report
10-Q
2025-08-05
View
Showing 1–15 of 131 filingsForm 4 / 144 hidden· 254 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001875558  |  Exchange: NASDAQ · Healthcare

Nuvectis Pharma, Inc. (NASDAQ: NVCT) has submitted 254 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2022. As a Healthcare sector company with CIK 0001875558, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Nuvectis Pharma, Inc.'s most comprehensive regulatory disclosure. The most recent Nuvectis Pharma, Inc. 10-K was filed on 2026-02-11 for fiscal year ending 2026. Historical NVCT 10-K annual reports are available from 2021 through 2026.

Investors researching Nuvectis Pharma, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

NVCT SEC Filings · 8 questions

Nuvectis Pharma, Inc. (NVCT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 254 filings and access original documents at no cost. Nuvectis Pharma, Inc.'s CIK is 0001875558.

NVCT SEC filingsNuvectis Pharma, Inc. SEC documentsfind NVCT 10-K